Abstract
2-((R-5-Chloro-4-methoxymethyl-indan-1-yl)-1H-imidazole (PF-3774076) is a central nervous system (CNS) penetrant, potent, selective, partial agonist at the human α1A-adrenoceptor, demonstrating efficacy and selectivity in a range of binding and functional assays. In vivo, PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner, inducing changes in both the proximal and distal portions of the urethra via a central mechanism of action. The profile of this compound suggests that a CNS penetrant partial agonist at the α1A-adrenoceptor may offer significant benefit in stress urinary incontinence (SUI). However, despite partial agonism at the α1A-adrenoceptor and selectivity over α1B- and α1D-adrenoceptors, PF-3774076 did not offer the necessary degree of separation over cardiovascular events when assessed in in vivo models of cardiovascular function. This may be due to activation of both peripheral and central α1A-adrenoceptors. These data indicate that although central, partial α1A-agonists may offer significant benefit in the treatment of SUI, it may not be possible to achieve the desired level of urethral selectivity over cardiovascular events with this class of agent.
Footnotes
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.109.154963.
-
ABBREVIATIONS: CCRC, cumulative concentration response curve; CHO, Chinese hamster ovary; CSF, cerebrospinal fluid; DMSO, dimethyl sulfoxide; LUT, lower urinary tract; SUI, stress urinary incontinence; PCR, polymerase chain reaction; RT-PCR, reverse transcription polymerase chain reaction; qRT-PCR, quantitative RT-PCR; PUP, peak urethral pressure; UPP, urethral pressure profile; PF-3774076, 2-((R-5-Chloro-4-methoxymethyl-indan-1-yl)-1H-imidazole; FLIPR, fluorometric imaging plate reader; Ro 115-1240, N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methylphenyl] methanesulfonamide.
-
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
- Received April 9, 2009.
- Accepted June 3, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|